Previous 10 | Next 10 |
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with this Read more ...
Preface Shares of Neurocrine Biosciences ( NBIX ) are up nearly 40% since I published the article , in December 2018, citing my belief that shares of NBIX would see $100 again. At that time, Neurocrine had revealed disappointing data in Tourette's and traded in the low $70s. Since then...
Neurocrine Biosciences (NASDAQ: NBIX ) initiated with Outperform rating and $118 (24% upside) price target at RBC. More news on: Neurocrine Biosciences, Inc., Regeneron Pharmaceuticals, Inc., Allergan plc, Healthcare stocks news, Stocks on the move, , Read more ...
AbbVie (NYSE: ABBV ) has filed a marketing application with the FDA seeking approval of Orilissa (elagolix) for the management of heavy menstrual bleeding associated with uterine fibroids. More news on: AbbVie Inc., Neurocrine Biosciences, Inc., Healthcare stocks news, Read more ... ...
NORTH CHICAGO, Ill. , Aug. 5, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Adminis...
Neurocrine Biosciences ( NBIX ) was never set up for a great year in 2019 from a clinical data/pipeline perspective, but management is compensating so far with strong sales execution with its approved drug Ingrezza. With the company now free cash flow positive, management has a lot of option...
The following slide deck was published by Neurocrine Biosciences, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Sigma Labs (NASDAQ: SGLB ) +19% to work with airbus to deploy PrintRite3D rapid test and evaluation program More news on: Sigma Labs, Inc., Valeritas Holdings, Inc., RingCentral, Inc., Stocks on the move, Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ) is up 8% premarket following its Q2 report released after the close yesterday. Highlights: More news on: Neurocrine Biosciences, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Neurocrine Biosciences, Inc. (NBIX) Q2 2019 Earnings Conference Call July 29, 2019, 16:30 ET Company Participants Kevin Gorman - CEO & Director Jane Sorensen - Head, IR Matthew Abernethy - CFO Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development &am...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...